Home>Topics>Companies>Orexigen Therapeutics

Orexigen Therapeutics

  1. All
  2. Commentary
  3. Headlines
  1. UPDATE 2-FDA delays decision on Orexigen's obesity drug by 3 months

    Headlines

    Wed, 11 Jun 2014

    June 11 (Reuters) - Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed a decision on the marketing application for its obesity drug, contrave, by three months, sending the...

  2. FDA delays decision on Orexigen's obesity drug by three months

    Headlines

    Wed, 11 Jun 2014

    June 11 (Reuters) - Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed its decision on the marketing application of its obesity drug, contrave, by three months, sending its...

  3. Diet drug makers Vivus, Orexigen fall ahead of FDA decision

    Headlines

    Tue, 17 Jul 2012

    (Reuters) - Shares of weight-loss drug makers Vivus Inc and Orexigen Therapeutics Inc fell ahead of an anticipated deadline by the end of Tuesday for the U.S. Food and Drug Administration to decide...

  4. Vivus, Orexigen diet pills show positive heart-safety

    Headlines

    Mon, 4 Apr 2011

    BANGALORE (Reuters) - After a spate of disappointments, weight-loss drugmakers Vivus Inc and Orexigen Therapeutics Inc said clinical data suggested reduced heart risks associated with diet pills,...

  5. Arena Rival Orexigen Needs Heart Safety Trial, Highlights Risks of Obesity Drug Development

    Commentary

    Tue, 1 Feb 2011

    Orexigen Therapeutics ' OREX stock took a nose dive Tuesday when the firm announced it received a complete response letter from the Food and Drug Administration

  6. EnteroMedics' Shares Rise on Optimism about Orexigen's Diet Drug

    Commentary

    Wed, 8 Dec 2010

    ETRM saw its shares run up substantially following a Food and Drug Administration panel decision to recommend approval of Orexigen 's OREX weight loss drug candidate Contrave. The panel's recommendation was somewhat surprising, especially since it had not

  7. Orexigen's Obesity Drug Receives Surprise Panel Recommendation; We Remain Negative on Arena

    Commentary

    Wed, 8 Dec 2010

    voted to recommend approval of Orexigen Therapeutics ' OREX diet drug Contrave. This comes ..... firms rose dramatically, with Orexigen up more than 100%, as the ..... believes that a positive sign for Orexigen could signal eventual approval

  8. Panel Ahead for Arena's drug

    Commentary

    Wed, 30 Jun 2010

    review for lorcaserin on September 16, about one month before the FDA action date on October 22. Another close competitor, Orexigen OREX , has a panel meeting for its drug Contrave set for December, well after Arena's action date. However, the Contrave

  9. Dropping Coverage of Orexigen

    Commentary

    Mon, 3 Aug 2009

    We are no longer providing equity research on Orexigen Therapeutics OREX . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.

  10. Orexigen's Pivotal Trials Meet Endpoint

    Commentary

    Mon, 20 Jul 2009

    Orexigen Therapeutics OREX announced Monday that its much-anticipated ..... compared with placebo, according to Orexigen 's final data. Despite relatively ..... headache. Consequently, we think Orexigen will have to surpass high hurdles

« Prev12Next »
Content Partners